Faculty Profiles

David F. Kisor, Pharm.D.
Department Chair of Pharmaceutical Sciences
260-470-2747
dfkisor@manchester.edu

Dr. David Kisor joined the College of Pharmacy in June 2014, and is responsible for facilitating teaching, scholarly activity, and service in the Department of Pharmaceutical Sciences as Chair. Dr. Kisor came to Manchester University from the Raabe College of Pharmacy at Ohio Northern University. He received his Bachelor of Science degree in Pharmacy from the University of Toledo and his Pharm.D. from The Ohio State University.

He has integrated PGt into pharmacokinetic subject matter since 1998. His research will be related to the PK and PGt of various compounds in the in-vitro and in-vivo settings. He is a member of the Clinical Pharmacogenetics Implementation Consortium (CPIC), American Society for Clinical Pharmacology and Therapeutics (ASCPT), the American College of Clinical Pharmacology (ACCP), the American Pharmacists Association (APhA), the American Association of Colleges of Pharmacy (AACP), the National Coalition for Healthcare Provider Education in Genetics (NCHPEG), and the Personalized Medicine Coalition (PMC). Dr. Kisor will also serve as Chair of the Pharmacogenetics Special Interest Group of AACP.


Classes Taught at Manchester

  • Integrated Pharmacotherpy Modules

Areas of interest/Recent projects

  • Development of faculty
  • Pharmacogenetics/Pharmacogenomics Implementation
  • Pharmacogenetics/Pharmacogenomics of cathinones
  • Pharmacokinetics of cathinones
  • Teaching pharmacokinetics and pharmacogenetics

Publications/Presentations/Posters

  • Book:
    Kisor DF, Kane, MD, Talbot JT, Sprague JE. Pharmacogenetics, Kinetics and Dynamics for Personalized Medicine. 1st Ed. Jones and Bartlett Learning. Burlington, MA. 2013.
  • Book Chapter:
    Benedict N, Kisor DF. The academic pharmacist in: Remington: The Science and Practice of Pharmacy. 22nd Ed. 2229-2234, 2013.
  • Invited Editorial:
    Kisor DF. Making personalized medicine an expectation of pharmacy students. Pers Med. 10(1):5-8, 2013.
  • Kisor DF. Collaboration to meet a therapeutic need: The development of nelarabine. Clin Med: Ther. 1:1317-1320, 2009.
  • Peer Reviewed /Professional:
    Kisor DF, Smith AJ. Therapeutic Actions and the Genetic Code: Examples of the application of pharmacogenetics. Ohio Pharmacist 62(12):7-12, 2013.
  • Kisor DF, Kroustos K. Pharmacogenomics in women’s health. U.S. Pharmacist. 38(9):70-80, 2013.
  • Kisor DF, Tice B. Implementing pharmacogenomics in pharmacy practice. Am Pharmacist 47-61, 2013.
  • Kisor DF, Sprague JE. The application of drug dosing guidelines based on preemptive genetic testing. Spec Pharm Times. 4(3), 2013.
  • Kisor DF, Munro C, Loudermilk E. Pharmacogenomics and the most commonly prescribed drugs of 2011. Pharm Times. 78(12), 2012.
  • Likovich M, Derr A, Kane M, Kisor DF, Sprague JE. Personalized medicine and the future of pharmacy practice. Pharm Times. 76(4), 2010.
  • Peer Reviewed Research/Reviews:
    Kisor DF, Bright DR, Conaway MM, Bouts BA, Gerschutz G. Pharmacogenetics in the Community Pharmacy: Thienopyridine Selection Post Coronary Artery Stent Placement. J Pharm Prac. Published online before print February 13, 2014, doi: 10.1177/0897190014522496.
  • Shields KM, Sobota KF, Kroustos KR, Bright DR, North CL, Kisor DF. Implementation and evaluation of a student-led, online, longitudinal outpatient case elective. Curr Pharm Teach Learn. 5(5);351-357, 2013.
  • Kisor DF, Talbot JN, Stockert AL, Smith A. Exploring a laboratory model of pharmacogenetics as applied to clinical decision making. Innov Pharm. 4(2);1-12, 2013.
  • Recent Presentations
    April 2014 – Pharmacogenetics: Clinical Application of Population and Individual Preemptive Genetic Data. Ohio Pharmacists Association 136th Annual Meeting, Columbus, Ohio. (invited)
  • March 2014 – Genetics and Drug Response. Kappa Psi Province V Annual Meeting, Lima, Ohio. (invited)
  • August 2013 – Integration of Pharmacogenetics into Community Pharmacy Workflow. RBC – Annual Pharmacy Business Conference. Seattle, Washington.
  • August 2013 – Review and Updates on Drug Interactions and Drug-Drug-Gene Interactions– OTCs and Prescription Drugs. RBC – Annual Pharmacy Business Conference. Seattle, Washington.
  • July 2013 – Introducing Pharmacogenomics and Personalized Medicine via a Blog. American Association of Colleges of Pharmacy Annual Meeting. Chicago, Illinois. (invited)
  • July 2013 – The Science Behind Pharmacogenomics. U.S. Department of Health and Human Services. Health Resources and Services Administration (HRSA). Patient Safety and Clinical Pharmacy Services Collaborative (PSPC). Webinar (Invited)
  • May 2013 – drugsandgenes.com. 2013 Cleveland Clinic Personalized Healthcare Summit: From concept to practice. (poster) Cleveland, Ohio
  • May 2013 – Pharmacogenetics and pharmacokinetics. 74th Annual Meeting of the Ohio Society of Health-System Pharmacists. Columbus, Ohio (invited)
  • March 2013 – St. Rita’s Medical Center. Pharmacogenetics: implications and implementation. Lima, Ohio (invited)
  • September 2012 – Nelarabine: A New Drug-DNA Antimetabolite. 2009-2012 T-Cell Lymphomas: work in progress. Bologna, Italy. (invited)
  • July 2012 – NIH-NHGRI Initiative: Pharmacist Education in the Era of Genomic Medicine; Barriers to and facilitators of pharmacogenomics education. American Association of Colleges of Pharmacy Annual Meeting. Orlando, Florida. (invited)
  • October 2011 – Personalized Medicine: The Pharmacogenetic-Pharmacokinetic Interface. Ohio Pharmacists Association Mid-Year Clinical Meeting, Columbus, Ohio. (invited)
MU College of Pharmacy on Facebook

© 2013 Manchester University
Manchester University College of Pharmacy
10627 Diebold Road, Fort Wayne, IN 46845
260-470-2700
MU Home